NasdaqGM:VERABiotechs
Vera Therapeutics Adds CCO As Atacicept Advances And Valuation Gap Persists
Vera Therapeutics (NasdaqGM:VERA) has appointed Matt Skelton as Chief Commercial Officer.
The move comes as the company prepares for potential commercialization of its lead drug, atacicept, for IgA nephropathy.
Atacicept has received Breakthrough Therapy Designation and Priority Review from the FDA.
Vera Therapeutics focuses on therapies for serious immunologic diseases, with atacicept as its lead asset in IgA nephropathy. The addition of a Chief Commercial Officer signals that management...